Arca
Skip to content
Tools
Tools

Rhinosinusitis

Drug research and approvals for rhinosinusitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 67 studies of rhinosinusitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 24 drug trials for it since 2013, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 67
  • Trials authorized in Canada: 24
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting now

Newest posted first, of 67 recruiting on ClinicalTrials.gov ↗

How its trials ended

378 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 76 whose ending is known, 36% met their primary endpoint, 5% missed it and 59% stopped early.

  • Completed, result not reported14939%
  • Ongoing10327%
  • Status unknown5013%
  • Met its primary endpoint277%
  • Stopped: other or unclear267%
  • Stopped: enrollment or feasibility113%
  • Stopped: lack of efficacy51%
  • Missed its primary endpoint41%
  • Stopped: funding21%
  • Stopped: sponsor or business decision1<1%

Trials authorized in Canada

The 10 newest of 24; search them all in Canada trials
Feb 24, 2026A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic…Itepekimab (SAR440340)Sanofi-Aventis Canada IncClosed
Oct 9, 2025The efficacy of intra-sinus povidone-iodine/budesonide gel forming suspension following endoscopic sinus surgery for chronic rhinosinusitis: a randomized,…Povidone iodine-budesonideSt Pauls Hospital VancouverOngoing
Dec 31, 2024Determining the immunologic impact of dupilumab on the unified airway system in patients suffering from asthma and chronic rhinosinusitis with polypsDupixentSt Paul's Sinus CentrePending
Dec 5, 2024A randomized, double-blind, placebo-controlled, parallel-group, 52-week phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in…SAR440340 (itepekimab)Sanofi-Aventis Canada IncOngoing
Dec 5, 2024A randomized, double-blind, placebo-controlled, parallel-group, 52-week phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in…SAR440340 (itepekimab)Sanofi-Aventis Canada IncClosed
Oct 29, 2024Opening the 'black box' on tezepelumab's effect of chronic rhinosinusitis with severe asthmaTezspireSt Paul's Sinus CentreOngoing
Oct 4, 2024A randomized, double-blind, placebo-controlled, proof-of-concept (POC) study to assess the efficacy, safety, and tolerability of itepekimab in participants…Itepekimab (SAR440340)Sanofi-Aventis Canada IncClosed
Apr 25, 2024A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of lebrikizumab/LY3650150 in…Lebrikizumab (LY3650150)Eli LillyOngoing
Aug 10, 2023Multicenter, randomized, double-blinded, placebo-controlled, phase 2 clinical efficacy study evaluating nitric oxide nasal spray (NONS) compared to saline…Nitric oxideSanotize Research & Development CorpOngoing
Aug 4, 2023A phase 2b, randomized, double-blind, placebo-controlled, multicenter study of the efficacy and safety of brensocatib in participants with chronic…Brensocatib (INS1007)InsmedClosed

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Dec 1, 2015NucalaMepolizumabGlaxoSmithKline Trading Services LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.